• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

UCLA Research Uses Saliva to Detect Cancer Biomarkers

by Syed Hamza Sohail 07/27/2022 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
UCLA Health’s COVID-19 Swab Shortage Solved With 3D-Printed Swabs

What You Should Know:

– Spectrum Solutions, LLC announced the publishing of findings from their research collaboration with the University of California at Los Angeles (UCLA) and Dr. David Wong, UCLA School of Dentistry that successfully demonstrated a superior ability to detect circulating tumor DNA (ctDNA) from saliva.

– Specifically, amplified EGFR mutations associated with non-small cell lung cancer (NSCLC) using Spectrum’s saliva collection and preservation system with the Electric Field–Induced Release and Measurement (EFRIM) electrostatic platform.

Detecting EGFR Mutations in Saliva

The published research, “Proficiency Testing of Epidermal Growth Factor Receptor Mutations Detection in Saliva Using Spectrum Saliva Collector (SDNA-1000) and Preservative Solution Detected by Electric Field-Induced Release and Measurement,” Feng Li et al, is an unprecedented feat in modern medicine.

Many advances in targeted treatments for lung cancer are based on the evaluation of three EGFR gene mutations. Current methods for diagnosis and monitoring include invasive tissue biopsies, which create clinical obstacles for ongoing mutation analysis and cancer treatment. The less invasive liquid biopsy options using free-floating cell-free DNA (cfDNA) or circulating tumor DNA (ctDNA) in solid tumor cancers have quickly become an important part of the screening, diagnosis and monitoring process for cancer patients.

When paired with new technology developed at UCLA by Dr. Wong, known as EFIRM, study findings have demonstrated an impressive 14-fold amplification of detectable usctDNA from saliva collected and stabilized using Spectrum’s SDNA-1000 compared to raw or neat saliva. Additionally, after diluting the signal down to 10 percent of the original concentration, the team continued to see enhanced amplification benefits from the Spectrum device, leading scientists to believe detection of a single ctDNA fragment may now be possible.

“The ability to detect EGFR mutations using ctDNA enables a broad range of clinical applications for laboratory medicine such as the early detection of disease, practical applications of personalized treatments, predicting treatment response and monitoring resistance,” said Rohit Gupta, Chief Medical Officer for Spectrum Solutions. “Proving it can be done using saliva is groundbreaking.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Biomarkers, cancer, dna, lung, Lung Cancer

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Particle Health Addresses Integration to Epic Data Despite Dispute

US Court Allows Particle’s Antitrust Claims Against Epic to Proceed

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Evernorth Health Services Invests $3.5B in Shields Health Solutions

Evernorth Health Services Invests $3.5B in Shields Health Solutions

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

M&A:Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

Femtech: Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

Sage Growth Partners Report: Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |